在oregoomab治疗的复发性卵巢癌患者中，CA125和肿瘤特异性t细胞应答与延长生存期相关。
文章的细节
-
引用
复制到剪贴板 -
戈登·安，舒尔特斯BC，加里昂H，爱德华兹R，怀特塞德TL，塞马克JM，尼哥德摩斯CF
在oregoomab治疗的复发性卵巢癌患者中，CA125和肿瘤特异性t细胞应答与延长生存期相关。
妇科肿瘤杂志2004年8月;94(2):340-51。
- PubMed ID
-
15297171 (查看PubMed］
- 摘要
-
目的:评价奥瑞戈单抗联合化疗治疗复发性卵巢癌患者的免疫反应和临床疗效。方法:晚期复发性卵巢癌患者在化疗前12周以上给予奥瑞戈单抗，然后选择性地与化疗同时进行x 2。ELISA法检测人抗小鼠抗体(HAMA)、抗独特型抗体(Ab2)和抗ca125;通过干扰素(IFN)- γ酶联免疫斑点(ELISPOT)评价t细胞对CA125、自体肿瘤和oregoomab的反应。记录临床结果。结果:入组患者20例;中位随访时间为15.8个月。oregoomab耐受性良好，未发生与药物相关的严重不良反应。在15/19(79%)的患者中，观察到对oregovomab的常量区(HAMA)和可变区(Ab2)的强有力的治疗应急体液反应，2/19(11%)的患者产生了抗ca125抗体。在7/18(39%)对CA125有反应的患者中，5/8(63%)对自体肿瘤有反应的患者中，9/18(50%)对oregovomab有反应的患者中，t细胞反应显著增加。 Immune responses appeared by week 12 (four doses) and were generally maintained or augmented in patients continuing combined treatment with oregovomab and chemotherapy. Median survival was 70.4 weeks (4.6-141.6 weeks), and the median progression-free interval was 11 weeks (2.6-114.6 weeks). Patients who mounted a T-cell response to CA125 and/or autologous tumor showed significantly improved survival (median not reached vs. 51.9 weeks, P = 0.002) compared to patients who did not. CONCLUSIONS: Oregovomab was well tolerated and induced multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit was observed in patients mounting a T-cell response to CA125 and/or autologous tumor.
引用本文的药库数据
- 药物